Outcomes4Me Inc., the developer of a personalized and evidence-based cancer navigation platform, and the National Comprehensive Cancer Network announced that Outcomes4Me has newly incorporated the NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer into its free app. The collaboration between Outcomes4Me and the NCCN dates back to 2019, when Outcomes4Me first integrated the NCCN Guidelines for Breast Cancer. In 2021, the two groups expanded their collaboration when Outcomes4Me added the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic into its app, which raised awareness for the importance of genetic cancer risk screening.
This latest extension of the years-long collaboration represents the formal launch of Outcomes4Me’s multi-cancer care efforts; its app is now fully available to lung cancer patients across the world, meeting an important need. Annually, there are more than 2 million new cases of lung cancer and 1.8 million people die from the disease globally. Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer cases. In the U.S., more people die of lung cancer each year than of colon, breast, and prostate cancers combined; however, there are new and effective treatment options that patients should have access to. The FDA has approved 39 lung cancer drugs since 2018, including eight new approvals in the last year. 10,663 lung cancer clinical trials are currently recruiting globally, with more than 4,000 of those trials recruiting in the U.S.
NCCN is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education; it represents the expertise of many of the world’s leading authorities on cancer treatment and innovation. With the expanded collaboration between NCCN and Outcomes4Me, breast and lung cancer patients can use the Outcomes4Me app to directly access the latest clinical guidance for their cancer, personalized to their unique diagnosis, and in a format they can understand––regardless of where they receive their care.
“Cancer innovation has never happened so quickly or shown as much promise as it does today,” said Maya R. Said, Sc.D., Founder and CEO at Outcomes4Me. “This should be a time of great excitement, but there is a troubling disconnect between innovation and clinical practice. We know from our own research that many patients are not benefitting from this innovation. After seeing the power of our NCCN content integration within the breast cancer community, we are thrilled to accelerate the dissemination of the latest science to lung cancer patients globally.”
SOURCE: PR Newswire